

CLAIMS

What is claimed is:

1. A humanized antibody specific for complement factor Bb, wherein the antibody comprises (a) light chain complementarity determining regions (CDRs) of an antibody light chain variable (VL) region comprising amino acid sequence SEQ ID NO:7 and (b) heavy chain CDRs of an antibody heavy chain variable (VH) region comprising amino acid sequence SEQ ID NO:8.
2. The humanized antibody of claim 1, wherein the antibody binds a human complement Bb protein with an affinity of at least 10^{-8} M.
3. The humanized antibody of claim 1 or 2, wherein the antibody inhibits C3b/Bb-mediated cleavage of C3.
4. The humanized antibody of any one of claims 1-3, wherein the antibody comprises a humanized light chain framework region and a humanized heavy chain framework region.
5. The humanized antibody of any one of claims 1-4, wherein the antibody is selected from the group consisting of an Ig monomer, a Fab fragment, a F(ab')₂ fragment, a scFv, a scAb, and a Fv.
6. The humanized antibody of any one of claims 1-5, wherein the antibody comprises a light chain region and a heavy chain region that are present in separate polypeptides.
7. The humanized antibody of any one of claims 1-5, wherein the antibody comprises a light chain region and a heavy chain region that are present in a single polypeptide.
8. A pharmaceutical composition comprising an antibody of any one of claims 1-7; and a pharmaceutically acceptable excipient.
9. A sterile container comprising the pharmaceutical composition of claim 8.

10. Use of the humanized antibody of any one of claims 1-7 or the pharmaceutical composition of claim 8 in the preparation of a medicament for treating an individual having a complement-mediated disease or disorder, wherein an effective amount of the medicament is to be administered to the individual.
11. The use of claim 10, wherein said medicament is to be administered intravenously.
12. The use of claim 10, wherein said medicament is to be administered subcutaneously.
13. The use of claim 10, wherein said medicament is to be administered intramuscularly.
14. The use of any one of claims 10-13, wherein the complement-mediated disease or disorder is atypical Hemolytic Uremic Syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH) lupus nephritis, ANCA associated vasculitis, membranous nephritis, or C3 Glomerulonephritis (C3GN).
15. An antibody comprising a light chain variable region that comprises amino acid sequence SEQ ID NO:7 and a heavy chain variable region that comprises amino acid sequence SEQ ID NO:8.